BRAF MUTATION

BRAF Mutation — the BRAF V600E oncogenic variant drives approximately 50% of melanomas and is found across colorectal, thyroid, lung, and hairy cell leukemia, with FDA-approved targeted BRAF+MEK inhibitors available for multiple cancer types.

Whole genome sequencing evaluates all BRAF variants — V600E, V600K, V600R, and rare non-V600 mutations — alongside germline BRAF variants that cause cardio-facio-cutaneous (CFC) syndrome, a RASopathy.

BRAF

About this condition

BRAF Mutation

BRAF (v-Raf murine sarcoma viral oncogene homolog B, chromosome 7q34) encodes a serine/threonine kinase in the RAS-RAF-MEK-ERK signaling pathway. The BRAF V600E mutation (valine to glutamic acid at position 600) is found in approximately 50% of melanomas, 8-12% of colorectal cancers, 45-60% of papillary thyroid cancers, 1-3% of non-small cell lung cancers, and nearly 100% of hairy cell leukemias. V600E constitutively activates the MAP kinase pathway, driving cell proliferation independent of upstream growth factor signals.

FDA-approved BRAF+MEK inhibitor combinations have transformed outcomes: dabrafenib+trametinib (melanoma, NSCLC, anaplastic thyroid cancer), vemurafenib+cobimetinib (melanoma), and encorafenib+binimetinib (melanoma and with cetuximab for CRC). In BRAF-mutant melanoma, BRAF+MEK inhibitor combinations produce response rates of ~65-70% with median PFS of ~12-14 months. Anti-PD-1 immunotherapy (pembrolizumab, nivolumab) is also highly effective in melanoma — with BRAF status influencing the sequencing of targeted therapy vs. immunotherapy.

In colorectal cancer, BRAF V600E has traditionally been a marker of poor prognosis. The BEACON trial demonstrated that encorafenib+cetuximab (±binimetinib) produced significant improvement in BRAF V600E-mutant metastatic CRC — making BRAF testing mandatory for all metastatic CRC patients. Germline BRAF variants are rare but cause cardio-facio-cutaneous (CFC) syndrome — a RASopathy characterized by cardiac defects, facial dysmorphism, ectodermal abnormalities, and intellectual disability.

BRAF V600E testing is mandatory for all metastatic melanoma and colorectal cancer patients — it determines whether targeted BRAF inhibitors are available. Missing BRAF V600E means missing a targeted therapy that produces ~70% response rates.

Gene locus: BRAF (7q34)

BRAF V600E opens the door to FDA-approved targeted therapies across melanoma, CRC, NSCLC, thyroid cancer, and hairy cell leukemia. WGS detects all BRAF variants from a single test and distinguishes somatic from germline.

BRAF status determines melanoma treatment sequencing — targeted therapy vs. immunotherapy first

BRAF V600E-mutant melanoma has two effective treatment paradigms: BRAF+MEK inhibitors (rapid response, finite duration) and anti-PD-1 immunotherapy (slower response, potentially durable). Treatment sequencing depends on disease tempo, tumor burden, and patient preference. BRAF-wild-type melanoma receives immunotherapy as the primary approach. Molecular BRAF status fundamentally determines the treatment discussion.

BRAF V600E in CRC was previously a death sentence — the BEACON combination transforms outcomes

BRAF V600E CRC has historically been the worst-prognosis molecular subtype. Standard chemotherapy produces median survival of ~6 months in the refractory setting. The BEACON regimen (encorafenib+cetuximab) demonstrated significantly improved survival — converting BRAF V600E from a purely prognostic marker to a target for effective therapy. Without BRAF testing, these CRC patients never receive the targeted combination.

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test